Article · UK Corporate Tax & R&D
CTA 2009 Chapter 2 worked example comparing 26.97% ERIS cash against 16.20% loss-making Merged RDEC, connected-company rules, and the 1-year grace period
For loss-making R&D-intensive SMEs (loss-making before the 86% additional deduction under CTA 2009 s. 1044(2A)), Enhanced R&D Intensive Support (ERIS) under CTA 2009 Part 13, Chapter 2 delivers up to 26.97% in immediate cash (86% additional deduction + 14.5% payable credit) for accounting periods beginning on or after 1 April 2024. That beats loss-making Merged RDEC (16.20%) by 10.77 percentage points in Year 1 cash, provided the company clears the 30% R&D intensity threshold.
Reduced from 40% (FY2023) to 30% for accounting periods beginning on or after 1 April 2024, the intensity ratio equals:
R&D Intensity = Qualifying R&D Expenditure (Company + Connected Companies) / Total Relevant Expenditure (Company + Connected Companies)
Total relevant expenditure includes all P&L expenses (including depreciation, share-based payments, and interest) plus capitalized qualifying R&D (s. 1308), aggregated across all connected companies under CTA 2010 s. 1122 (eliminating intercompany double-counting). Importantly, Finance Act 2024 abolished the legacy subsidised expenditure exclusion for both Merged RDEC and ERIS (subject only to the Northern Ireland Windsor Framework de minimis cap in s. 1112J).
Fenland BioCompute Ltd (autonomous SME, £1,450,000 revenue, £2,500,000 total relevant expenditure, -£1,050,000 pre-R&D loss) incurs £850,000 of qualifying R&D, achieving an intensity of 34.00% (>= 30.00%):
| Metric (Fenland BioCompute Ltd) | ERIS (Ch. 2) | Merged RDEC (Ch. 1A) | Variance |
|---|---|---|---|
| Additional Deduction (86%) / Gross RDEC (20%) | £731,000 | £170,000 | - |
| Surrenderable Loss / Step 2 Notional Tax (19%) | £1,581,000 | £32,300 | - |
| Immediate Cash Payable by HMRC | £229,245 (26.97%) | £137,700 (16.20%) | +£91,545 |
| Trading Loss Carried Forward | £200,000 | £880,000 | -£680,000 |
| Step 2 CT Carry-Forward Pool (s. 1042L) | £0 | £32,300 | -£32,300 |
| Undiscounted Total Value at 25% Future CT | £279,245 | £390,000 | -£110,755 |
If Fenland's intensity dips to 27.50% in Year 2 (£770,000 / £2,800,000), the CTA 2009 s. 1045ZA(6) one-year grace period preserves ERIS eligibility for Year 2, delivering £207,669 instead of £124,740 under Merged RDEC (an extra £82,929 in non-dilutive cash). Strategically, ERIS 100% cash surrender wins decisively on NPV for venture-backed biotechs facing 4+ years to profitability, whereas a temporary loss-maker returning to 25% CT within 1-2 years should carry forward losses or use partial surrender.
Run your own UK R&D figures through the live 7-step Merged RDEC, ERIS 30% intensity, and PAYE/NIC cap model in UK_RD_Merged_RDEC_ERIS_Calculator.xlsx, or read the complete 15-chapter practitioner reference in The UK R&D Tax Relief Handbook.
Previous: UK Merged RDEC 20% Seven-Step Calculation
Next: UK R&D Contracted-Out Rules, Overseas Restrictions, and PAYE/NIC Cap
Related UK corporate tax handbooks: UK Corporate Interest Restriction · UK VAT Partial Exemption · OECD Pillar Two